bluuebunny/crossref_metadata_2025 huggingface dataset:
The Tartu Summer School in Semiotics 2013
Authors: Randviir Anti
Published: September 2014

This article provides an overview of the 8th Tartu Semiotics Summer School (in the series of summer schools established in 1964 by Juri Lotman). The event took place at Kääriku, Estonia, August 18-23, 2013, and was dedicated to the publication of the collective manifesto (titled Theses on the Semiotic Study of Cultures) that in 1973 established the field of the semiotics of culture. The scientific focus of the discussions and presentations concerned, from a semiotic point of view, the processes of autocommunication
The Influence of Measures of Economic Freedom on FDI: A Comparison of Western Europe and Sub-Saharan Africa
Authors: Fofana Mory Fodé
Published: September 2014

This research found that recent efforts aimed at stimulating both domestic and foreign investment have attached great importance to the improvement of the regulatory framework and institutions of economic freedom. From the empirical perspective, benchmarking panel data of two samples of countries of Sub-Saharan Africa and Western Europe was used to assess the disaggregated effect of the regulatory variables of economic freedom on FDI. The results indicate that institutional variables of economic freedom are important in attracting FDI for both Europe and Africa. However, the specific variables that are statistically significant depend on the current state of development of the countries in the samples. These results are useful for comparing and identifying the priorities of the regulatory framework reforms for improving economic performance.
The role of serum amyloid A and sphingosine-1-phosphate on high-density lipoprotein functionality
Authors: Prüfer Nicole , Kleuser Burkhard , van der Giet Markus
Published: September 2014

The high-density lipoprotein (HDL) is one of the most important endogenous cardiovascular protective markers. HDL is an attractive target in the search for new pharmaceutical therapies and in the prevention of cardiovascular events. Some of HDL’s anti-atherogenic properties are related to the signaling molecule sphingosine-1-phosphate (S1P), which plays an important role in vascular homeostasis. However, for different patient populations it seems more complicated. Significant changes in HDL’s protective potency are reduced under pathologic conditions and HDL might even serve as a proatherogenic particle. Under uremic conditions especially there is a change in the compounds associated with HDL. S1P is reduced and acute phase proteins such as serum amyloid A (SAA) are found to be elevated in HDL. The conversion of HDL in inflammation changes the functional properties of HDL. High amounts of SAA are associated with the occurrence of cardiovascular diseases such as atherosclerosis. SAA has potent pro-atherogenic properties, which may have impact on HDL’s biological functions, including cholesterol efflux capacity, antioxidative and anti-inflammatory activities. This review focuses on two molecules that affect the functionality of HDL. The balance between functional and dysfunctional HDL is disturbed after the loss of the protective sphingolipid molecule S1P and the accumulation of the acute-phase protein SAA. This review also summarizes the biological activities of lipid-free and lipid-bound SAA and its impact on HDL function.
Utilization of a novel electrochemical 90Sr/90Y generator for the preparation of 90Y-labeled RGD peptide dimer in clinically relevant dose
Authors: Chakraborty Sudipta , Chakravarty Rubel , Sarma Haladhar Dev , Pillai Maroor Raghavan Ambikalmajan , Ashutosh Dash
Published: September 2014

The work reported in this paper provides a systematic study towards
the development of an optimized strategy for preparation of
a clinically relevant dose of 90Y-labeled dimeric RGD
peptide derivative, DOTA-E[c(RGDfK)]2 [DOTA-(RGD)2] for
in vivo targeted therapy utilizing 90Y obtained
from a novel electrochemical 90Sr/90Y
generator. The performance of the generator was evaluated to ensure
its suitability for providing 90Y in adequate quantity and
purity required for formulation of clinically relevant dose for
PRRT. 90Y-DOTA-(RGD)2 was synthesized in high yield
(86.2 ± 2.5%) and radiochemical purity
(98.4 ± 0.5%) using clinically relevant dose
(∼3.8 GBq) of 90Y. In vitro
stability studies revealed that the radiolabeled conjugate retained
its radiochemical purity in normal saline and human serum. Preliminary
biodistribution studies carried out in C57/BL6 mice bearing melanoma
tumors showed that the preparation exhibited significant tumor uptake
(5.30 ± 0.78% of injected activity at 30 min
post-injection) with good tumor to background ratio. The optimized
radiolabeling protocol seems to be an attractive strategy which is
largely viewed as a springboard to realize scope of developing
90Y labeled cyclic RGD peptides for targeted therapy of
tumors over-expressing integrin-α

v

β
3 receptors.
Crystal structure of sodium cadmium diaqua catena-[monoborodiphosphate]- hydrate, NaCd(H2O)2[BP2O8] · 0.8H2O
Authors: Ge M.-H. , Mi J.-X. , Huang Y.-X. , Zhao J.-T. , Kniep R.
Published: September 2014

BCdH6NaO10.8P2, hexagonal, P6122 (No. 178), a = 9.713(1) Å, c = 16.136(3) Å, V = 1318.4 Å3, Z = 6, Rgt(F) = 0.047, wRref(F2) = 0.105, T = 273 K.
Crystal structure of caesium gallium(III) catena-[monohydrogenmonoborate- bis(monophosphate)], CsGa[BP2O8(OH)]
Authors: Mi J.-X. , Borrmann H. , Huang Y.-X. , Mao S.-Y. , Zhao J.-T. , Kniep R.
Published: September 2014

BCsGaHO9P2, monoclinic, P121/c1 (No. 14), a = 9.259(1) Å, b = 8.6462(9) Å, c = 9.615(1) Å, = 103.059(6)0, V = 749.8 Å3, Z = 4, Rgt(F) = 0.050, wRref(F2) = 0.104, T = 295 K.
Crystal structure of Boc-L-Ile-ΔPhe-Ile-OCH3, C27H41N3O6 · H2O
Authors: Makker J. , Dey S. , Kumar P. , Singh T. P.
Published: September 2014

C27H43N3O7, orthorhombic, P21212 (No. 18), a = 12.202(1) Å, b = 27.790(1) Å, c = 9.128(1) Å, V = 3095.2 Å3, Z = 4, Rgt(F) = 0.054, wRref(F2) = 0.180, T = 293 K.
Crystal structure of tetrakis(isopropylamino)silane, Si(NHC3H7)4
Authors: Engering J. , Nuss J. , Jansen M.
Published: September 2014

C12H32N4Si, monoclinic, C121 (No. 5), a = 19.041(4) Å, b = 5.211(1) Å, c = 9.187(2) Å, β = 111.60(2)°, V = 847.6 Å3, Z = 2, Rgt(F) = 0.051, wRref(F2) = 0.061, T = 293 K.
Crystal structure of monoaqua(1,10-phenanthroline-N,N′)- succinatocobalt(II), Co(H2O)(C12H8N2)(C4H4O4)
Authors: Zheng Y.-Q. , Kong Z.-P.
Published: September 2014

C16H14CoN2O5, triclinic, P1 (No. 2), a = 7.499(1) Å, b = 10.270(1) Å, c = 10.490(1) Å, α = 97.65(1)°, β = 106.80(1)°, γ = 100.57(1)°, V = 745.3 Å3, Z = 2, Rgt(F) = 0.058, wRref(F2) = 0.151, T = 293 K.
Crystal structure of diaqua-bis[N-(2-pyridyl)carbonylaniline]copper(II) dinitrate, Cu(C12H16N2O)2(H2O)2(NO3)2
Authors: Ramazani A. , Morsali A.
Published: September 2014

C24H24CuN6O10, monoclinic, P121/c1 (No. 14), a = 7.441(2) Å, b = 11.458(2) Å, c = 14.850(3) Å, β = 95.941(5)°, V = 1259.4 Å3, Z = 2, Rgt(F) = 0.049, wRref(F2) = 0.126, T = 120 K.
Crystal structure of 2,2-dibenzyl-1,3-dimethyloxypropane, C19H24O2
Authors: Feng Y.-L.
Published: September 2014

C19H24O2, monoclinic, P121/n1 (No. 14), a = 8.408(2) Å, b = 13.915(3) Å, c = 14.456(3) Å, β = 93.15(3)°, V = 1688.8 Å3, Z = 4, Rgt(F) = 0.042, wRref(F2) = 0.111, T = 293 K.
Crystal structure of ethylenediaminesilver(I) 4-nitrobenzoate hemi-hydrate, Ag(C2H8N2)(C7H4NO4) · 0.5H2O
Authors: Zhu H.-L. , Wang X.-J. , Sun X.-J. , Wang D.-Q.
Published: September 2014

C9H13AgN3O4.50, monoclinic, C12/c1 (No. 15), a = 8.331(2) Å, b = 11.645(2) Å, c = 23.947(5) Å, β = 94.845(3)°, V = 2314.8 Å3, Z = 8, Rgt(F) = 0.030, wRref(F2) = 0.072, T = 298 K.
Crystal structure of ethylenediammonium di(4-chlor-benzoate), (C2H10N2)(C7H4O2Cl)2
Authors: Xia J. , Wang X.-J. , Sun X.-J. , Zhu H.-L. , Wang D.-Q.
Published: September 2014

C16H18Cl2N2O4, monoclinic, C12/c1 (No. 15), a = 21.92(1) Å, b = 9.015(5) Å, c = 8.620(5) Å, β = 96.151(9)°, V = 1693.3 Å3, Z = 4, Rgt(F) = 0.064, wRref(F2) = 0.186, T = 298 K.
Crystal structure of bis[N-(2-aminopropyl)-salicylaldiminato)]cobalt(III) perchlorate, C20H26ClCoN4O6
Authors: Zhu H.-L. , Liu W.-.J. , Wang Y.-F. , Wang D.-Q.
Published: September 2014

C20H26ClCoN4O6, monoclinic, P121/c1 (No. 14), a = 9.703(4) Å, b = 24.323(9) Å, c = 10.289(4) Å, β = 111.561(6)°, V = 2258.4 Å3, Z = 4, Rgt(F) = 0.049, wRref(F2) = 0.110, T = 298 K
Refinement of the crystal structure of silver(I) thiocyanate, AgSCN
Authors: Zhu H.-L. , Liu G.-F. , Meng F.-J
Published: September 2014

AgCNS, monoclinic, C12/c1 (No. 15), a = 8.792(5) Å, b = 7.998(5) Å, c = 8.207(5) Å, β= 93.75(1)°, V = 575.9 Å3, Z = 8, Rgt(F) = 0.049, wRref(F2) = 0.086, T = 293 K.
Crystal structure of dilanthanum pentaiodide, La2I5
Authors: Mattausch Hj. , Oeckler O. , Simon A.
Published: September 2014

I5La2, monoclinic, P121/m1(No. 11), a = 8.618(2)Å, b = 4.4038(9)Å, c = 14.580(3) Å, β = 90.20(3)°, V = 553.3 Å3, Z = 2, Rgt(F) = 0.026, wRref(F2) = 0.059, T = 293 K.
Crystal structure of tetraterbium hexabromide monosilicide, Tb4Br6Si
Authors: Mattausch Hj. , Oeckler O. , Simon A.
Published: September 2014

Br6SiTb4, orthorhombic, Pbam (No. 55), a = 13.061(1) Å, b = 13.859(2) Å, c = 4.0407(4) Å, V = 731.4 Å3, Z = 2, Rgt(F) = 0.029, wRref(F2) = 0.071, T = 293 K.
Crystal structure of distrontium lithium magnesium trisilicide, Sr2(LixMg2-x)Si3 (x = 1)
Authors: Xie Q.-X. , Nesper R.
Published: September 2014

LiMgSi3Sr2, orthorhombic, Cmcm (No. 63), a = 4.6179(5) Å, b = 19.488(2) Å, c = 7.1618(8) Å, V = 644.5 Å3, Z = 4, Rgt(F) = 0.029, wRref(F2) = 0.063, T = 293 K.
Refinement of the crystal structure of zirconium tritellurate(IV), ZrTe3O8
Authors: Noguera O. , Thomas P. , Masson O. , Champarnaud-Mesjard J.-C.
Published: September 2014

O8Te3Zr, cubic, Ia3̅ (No. 206), a = 11.308(1) Å, V = 1446.0Å3, Z = 8, ρm= 5.50(3) g·cm-3, Rgt(F) = 0.024, wRref(F2) = 0.049, T = 293 K.
Crystal structure of tetraaquasamarium(III) tri(2-chlorofumarate) hexahydrate, Sm2(COOCHCClCOO)3(H2O)4 · 6H2O, with two-dimensional net structure
Authors: Zhao M.-G. , Shi J.-M. , Yu W.-T.
Published: September 2014

C12H23Cl3O22Sm2, triclinic, P1 (No. 2), a = 8.877(3) Å, b = 9.413(3) Å, c = 9.554(3) Å, α = 103.778(5)°, β = 101.31 (5)°, ϒ = 93.954(5)°, V = 754.7 Å3, Z = 1, Rgt(F) = 0.056, wRref(F2) = 0.152, T = 293 K.
Crystal structure of ethylenediaminesilver(I) perchlorate, C2H8N2Ag(ClO4)
Authors: Zhu H.-L. , Zhang X.-M. , Yu Q. , Wang D.-Q.
Published: September 2014

C2H8AgClN2O4, monoclinic, P121/n1 (No. 14), a = 8.676(3) Å, b = 9.869(3) Å, c = 8.822(3) Å, β = 111.240(4)°, V = 704.1 Å3, Z = 4, Rgt(F) = 0.032, wRref(F2) = 0.063, T = 293 K.
Crystal structure of bis(1-phenylimidazolium) tetrachlorocuprate(II), (C9H9N2)2(CuCl4)
Authors: Casellato U. , Ettorre R. , Graziani R.
Published: September 2014

C18H18Cl4CuN4, monoclinic, C121 (No. 5), a = 14.109(3) Å, b = 10.263(2) Å, c = 15.290(3) Å, β = 102.61(3)°, V = 2160.6Å3, Z = 4, Rgt(F) = 0.040, wRall(F2) = 0.124, T = 293 K.
Crystal structure of [bis-tris(pyrazolyl)methanecopper(II)] [chlorobis( η2-benzoato)-η1-benzoato-manganate(II)] hydrate, Cu(C10H10N6)Mn(C7H5O2)3Cl · H2O
Authors: Moubaraki B. , Murray K. S. ,   Tiekink
Published: September 2014

C41H37ClCuMnN12O7, monoclinic, P121/n1 (No. 14), a = 15.946(3) Å, b = 13.26(2) Å, c = 20.766(5) Å, β = 106.49(2)°, V = 4209.3 Å3, Z = 4, Rgt(F) = 0.060, wRref(F2) = 0.155, T = 293 K.
Crystal structure of 3-(2,6-dichlorophenyl)-4,5-dihydro-7Hpyrano[ 4,3-d]isoxazol-7-one, C12H7Cl2NO3
Authors: Easton C. J. , Hughes C. M. M. , Tiekink E. R. T.
Published: September 2014

C12H7Cl2NO3, monoclinic, P121/n1 (No. 14), a = 7.499(4) Å, b = 14.450(4) Å, c = 21.559(3) Å, β = 96.89(2)°, V = 2319.3Å3, Z = 8, Rgt(F) = 0.054, wRref(F2) = 0.134, T = 293 K.
Crystal structure of discandium tris-monohydrogenphosphate(III), Sc2(HPO3)3
Authors: Ewald B. , Prots Yu. , Kniep R.
Published: September 2014

H3O9P3Sc2, hexagonal, P63/m (No. 176), a = 8.3055(7) Å, c = 7.697(1) Å, V = 459.8 Å3, Z = 2, Rgt(F) = 0.028, wRref(F2) = 0.061, T = 293 K.
Crystal structure of dirubidium dichromate(VI), Rb2Cr2O7, a fourth polymorph
Authors: Kolitsch U.
Published: September 2014

Cr2O7Rb2, triclinic, P1̅ (No. 2), a = 7.433(1) Å, b = 7.571(2) Å, c = 7.832(2) Å, α = 109.44(3)°, β = 90.81(3)°, γ = 108.89(3)°, V = 389.6 Å3, Z = 2, Rgt(F) = 0.028, wRref(F2) = 0.076, T = 293 K.
Refinement of the crystal structure of Sb-I, at 2.22 GPa
Authors: Akselrud L. G. , Hanfland M. , Schwarz U.
Published: September 2014

Sb, trigonal, R3̅m(No. 166), a = 4.2687(2) Å, c = 10.9244(6) Å, V = 172.4 Å3, Z = 6, R(P) = 0.066, R(I) = 0.059, T = 295 K, P = 2.22 GPa.
Refinement of the crystal structure of Bi-II, at 2.54 GPa
Authors: Akselrud L. G. , Hanfland M. , Schwarz U.
Published: September 2014

Bi, monoclinic, C12/m1 (No. 12), a = 6.67256(1) Å, b = 6.1108(2) Å, c = 3.30013(9) Å, β = 110.412(2)°, V = 126.1 Å3, Z = 4, R(P) = 0.118, R(I) = 0.087, T = 295 K, P = 2.54 GPa.
Crystal structure of 4,4′-bipyridinum dibromide, (C10H10N2)Br2
Authors: Zhang B.-S. , Zheng Y.-Q.
Published: September 2014

C10H10Br2N2, triclinic, P1̅(No. 2), a = 4.8975(6) Å, b = 7.654(1) Å, c = 7.9711(9) Å, α = 70.468(9)°, β = 87.029(9)°, γ = 77.15(1)°, V = 274.5 Å3, Z = 1, Rgt(F) = 0.034, wRref(F2) = 0.091, T = 293 K.
Refinement of the crystal structure of the δ-modification of tris(8-hydroxyquinoline) aluminum(III), δ-Al(C9H6NO)3, the blue luminescent Alq3
Authors: Rajeswaran M. , Blanton T. N. , Klubek K. P.
Published: September 2014

C27H18AlN3O3, triclinic, P1̅̅̅̅̅ (No. 2), a = 6.181(1) Å, b = 13.268(3) Å, c = 14.430(3) Å, α = 66.06(3)°, β = 88.56(3)°, γ = 84.03(3)°, V = 1075.5 Å3, Z = 2, Rgt(F) = 0.108, wRref(F2) = 0.437, T = 293 K.
Crystal structure of di[potassium(diaza-18-crown-6)]dicaesium nonastannide( 4–) diethylenediamine, [K(C12H26N2O4)]2Cs2[Sn9] · 2C2N2H8, a polyanion 2∞[KCs2Sn9]– with low-dimensional arrangement of [Sn9] clusters
Authors: Hauptmann R. , Fässler T. F.
Published: September 2014

C28H68Cs2K2N8O8Sn9, monoclinic, P121/c1 (No. 14), a = 13.897(3) Å, b = 16.091(3) Å, c = 26.432(5) Å, β = 91.03(3)°, V = 5909.7 Å3, Z = 4, Rgt(F) = 0.050, wRref(F2) = 0.127, T = 153 K.
Crystal structure of di[potassium(18-crown-6)]dipotassium nonastannide(4–)—diethylenediamine solvate (1:1.5), [K(C12H24O6)]2K2[Sn9] · 1.5C2N2H8
Authors: Hauptmann R. , Fässler T. F.
Published: September 2014

C27H60K4N3O12Sn9, monoclinic, P121/n1(No. 14), a = 10.410(2) Å, b = 25.659(5) Å, c = 20.636(4) Å, β = 102.56(3)°, V = 5380.2 Å3, Z = 4, Rgt(F) = 0.030, wRref(F2) = 0.072, T = 150 K.
Crystal structure of di[potassium([2.2.2]crypt)]tetrapotassium octadecagermanide(6–)—ethylenediamine solvate (1:6), [K(C18H36N2O6)]2K4(Ge9)2 · 6C2N2H8
Authors: Hauptmann R. , Fässler T. F.
Published: September 2014

C24H60Ge9K3N8O6, triclinic, P1̅ (No. 2), a = 9.408(2) Å, b = 13.606(3) Å, c = 19.507(4) Å, α = 84.74(3)°, β = 81.35(3)°, γ = 80.18(3)°, V = 2426.8 Å3, Z = 2, Rgt(F) = 0.064, wRref(F2) = 0.192, T = 150 K.
Crystal structure of dimethylamido-hexahydro-2-azepinato-bis[2-(trimethylsilylamino)-4-methylpyridinato]-titanium(IV), C26H46N6OSi2Ti
Authors: Kempe R. , Hillebrand G.
Published: September 2014

C26H46N6OSi2Ti, triclinic, P1̅ (No. 2), a = 10.178(2) Å, b = 10.906(2) Å, c = 16.254(3) Å, α = 91.82(1)°, β = 102.60(2)°, γ = 112.81(2)°, V = 1609.5 Å3, Z = 2, Rgt(F) = 0.046, wRobs(F2) = 0.116, T = 293 K.
Crystal structure of ammonium oxo(peroxo)(pyridine-2,6-dicarboxylato- N,O,O′)aquavanadate(V), (NH4)[VO(O2)(H2O)(C7H3NO4)]
Authors: Tinant B. , Bayot D. , Devillers M.
Published: September 2014

C7H9N2O8V, orthorhombic, Pcca (No. 54), a = 13.575(4) Å, b = 20.603(6) Å, c = 8.026(3) Å, V = 2244.8 Å3, Z = 8, Rgt(F) = 0.046, wRref(F2) = 0.155, T = 293 K.
Crystal structure of tris(N-(n-butyl)-4-methoxy-2-hydroxybenzaldimine)-tris(nitrato)lanthanum(III), La(C12H17NO2)3(NO3)3
Authors: Van Meervelt L. , Uytterhoeven K. , Van Deun R. , Binnemans K.
Published: September 2014

C36H51LaN6O15, triclinic, P1̅̅ (No. 2), a = 11.455(2) Å, b = 13.859(3) Å, c = 14.101(4) Å, α = 98.50(2)°, β = 98.87(1)°, γ = 92.52(2)°, V = 2182.4 Å3, Z = 2, Rgt(F) = 0.035, wRref(F2) = 0.082, T = 289 K.
Crystal structure of di(μ-3,5-dinitrobenzoato-O,O′)di(μ-3,5-dinitrobenzoato-O,O:O′)di(3,5-dinitrobenzoato-O,O′)di(1,10-phenanthroline- N,N′)-diterbium(III), Tb2(C12H8N2)2(C7H3N2O6)6
Authors: Hu M.-L. , Xiao H.-P. , Wang S. , Li X.-H.
Published: September 2014

C66H34N16O36Tb2, triclinic, P1̅̅ (No. 2), a = 12.027(7) Å, b = 12.908(7) Å, c = 13.210(7) Å, α = 104.086(7)°, β = 113.774(7)°, γ = 100.425(7)°, V = 1728.1 Å3, Z = 1, Rgt(F) = 0.025, wRref(F2) = 0.042, T = 298 K.
Crystal structure of diethylenetriaminesilver(I) perchlorate, Ag(C4H13N3)(ClO4)
Authors: Zhu H.-L. , Shao S.-C. , Ma J.-L. , Qiu X.-Y. , Yang S. , Sun L.
Published: September 2014

C4H13AgClN3O4, orthorhombic, Pccn (No. 56), a = 17.730(7) Å, b = 7.162(3) Å, c = 15.891(7) Å, V = 2017.9 Å3, Z = 8, Rgt(F) = 0.047, wRref(F2) = 0.152, T = 298 K.
Crystal structure of bis[dinitrato-2,5,8-triaza-1,9-di(2-fluorobenzylnonanecopper( II)] monohydrate, Cu(C18H22F2N5O6)2 · H2O
Authors: Zhu H.-L. , Shao S.-C. , Ma J.-L. , Qiu X.-Y. , Yang S. , Sun L.
Published: September 2014

C36H48Cu2F4N10O13, monoclinic, C1c1 (No. 9), a = 14.870(8) Å, b = 20.78(1) Å, c = 14.660(7) Å, β = 101.308(9)°, V = 4441.6 Å3, Z = 4, Rgt(F) = 0.053, wRref(F2) = 0.147, T = 298 K.
Crystal structure of di(2-aminopyridine)-tetrakis[N-(2-aminopropyl)-salicylaldiminato)]tricobalt(III) diperchlorate, Co3(C58H48N12O4)(ClO4)2
Authors: Zhu H.-L. , Yang S. , Shao S.-C. , Ma J.-L. , Qiu X.-Y. , Sun L.
Published: September 2014

C58H48Cl2Co3N12O12, triclinic, P1̅̅̅̅ (No. 2), a = 11.640(3) Å, b = 11.693(3) Å, c = 12.218(3) Å, α = 78.968(5)°, β = 89.827(5)°, γ = 60.605(4)°, V = 1414.0 Å3, Z = 1, Rgt(F) = 0.062, wRref(F2) = 0.136, T = 293 K.
Crystal structure of bis(3,3′-diethyl-4-maleimidophenyl)methane, C25H22N2O4
Authors: Zhu H.-L. , Zhang H. , Ma J.-L. , Qiu X.-Y. , Yang S. , Sun L.
Published: September 2014

C25H22N2O4, orthorhombic, Pccn (No. 56), a = 12.745(2) Å, b = 16.974(2) Å, c = 10.218(1) Å, V = 2210.4 Å3, Z = 4, Rgt(F) = 0.114, wRref(F2) = 0.300, T = 293 K.
Crystal structure of dimethylglyoxime 2-picoloylhydrazone, C10H12N4O2
Authors: Lin H. , Wu W.-S.
Published: September 2014

C10H12N4O2, monoclinic, P121/c1 (No. 14), a = 5.7138(3) Å, b = 25.771(1) Å, c = 7.3379(4) Å, β = 100.385(2)°, V = 1062.8 Å3, Z = 4, Rgt(F) = 0.051, wRref(F2) = 0.170, T = 293 K.
Crystal structure of [bis(2-hydroxybenzylidenethiosemicarbazone)-iron(II)] hydrate, Fe(C16H16N6O2S2) · H2O
Authors: Wu W.-S. , Feng Y.-L.
Published: September 2014

C16H18FeN6O3S2, monoclinic, P121/n1 (No. 14), a = 8.9754(5) Å, b = 18.229(1) Å, c = 11.5546(7) Å, β = 93.006(2)°, V = 1887.9 Å3, Z = 4, Rgt(F) = 0.039, wRref(F2) = 0.080, T = 293 K.
Crystal structure of diaqua-bis(pyridine)-μ2-squarato(1,3)-nickel(II), Ni(C4O4)(C5H5N)2(H2O)2
Authors: Kirchmaier R. , Altin E. , Lentz A.
Published: September 2014

C14H14N2NiO6, orthorhombic, Pbca (No. 61), a = 7.914(1) Å, b = 12.020(2) Å, c = 15.718(3) Å, V = 1495.3 Å3, Z = 4, Rgt(F) = 0.026, wRref(F2) = 0.062, T = 293 K.
Crystal structure of nonafluoro-{N-[(E)-2-(4-hydroxyphenyl)diazenyl]-phenyl}-1-butanesulfonamide, C16H10F9N3O3S
Authors: Àlvarez Micó X. , Richter M. , Schwarz S. , Strähle J. , Ziegler T. , Subramanian L. R.
Published: September 2014

C16H10F9N3O3S, triclinic, P1̅ (No. 2), a = 5.4635(2) Å, b = 10.266(1) Å, c = 17.645(2) Å, α = 105.731(6)°, β = 93.187(5)°, γ = 97.036(7)°, V = 941.3 Å3, Z = 2, Rgt(F) = 0.048, wRref(F2) = 0.134, T = 213 K.
Crystal structure of (±)-[(2R,3S)-3-(hydroxymethyl)oxiran-2-yl](phenyl)- methanone, C10H10O3
Authors: Greatrex B. W. , Taylor D. K. , Tiekink E. R. T.
Published: September 2014

C10H10O3, orthorhombic, Pca21 (No. 29), a = 20.165(4) Å, b = 5.667(1) Å, c = 7.583(2) Å, V = 866.6 Å3, Z = 4, Rgt(F) = 0.072, wRref(F2) = 0.177, T = 223 K.
Crystal structure of the antibiotic SY-1 (20-deoxy-salinomycin): sodium 2-(6-[2- (5-ethyl-5-hydroxy-6-methyl-tetrahydro-pyran-2-yl)-2,10,12-trimethyl- 1,6,8-trioxa-dispiro[4.1.5.3]pentadec-13-en-9-yl]-2-hydroxy-1,3-dimethyl-4-oxo-heptyl-5-methyl-tetrahydro-pyran-2-yl)-butyrate—methanol solvate (1:0.69), C42H69NaO10 · 0.69CH3OH
Authors: Paulus E. F. , Vértesy L.
Published: September 2014

C42.693H71.772NaO10.693, orthorhombic, P212121 (No. 19), a = 11.295(1) Å, b = 18.628(1) Å, c = 21.823(1) Å, V = 4591.6 Å3, Z = 4, Rgt(F) = 0.037, wRref(F2) = 0.099, T = 293 K.
Crystal structure of di(1,10-phenanthroline-N,N′)di[μ-(2-furancarboxylato- O,O′)-μ-(2-furancarboxylato-O,O′:O′)]di(nitrato)disamarium(III), Sm2(NO)2(C5H3O3)4(C12H8N2)2
Authors: Li X. , Zou Y.-Q. , Song H.-B.
Published: September 2014

C22H14N3O9Sm, triclinic, P1̅ (no. 2), a = 10.400(4) Å, b = 10.584(4) Å, c = 11.093(4) Å, α = 81.437(6)°, β = 88.599(6)°, γ = 67.888(5)°, V = 1118.0 Å3, Z = 2, Rgt(F) = 0.036, wRref(F2) = 0.069, T = 293 K.
Refinement of the crystal structure of zirconium monobismuthide, ZrBi
Authors: Boström M. , Prots Yu. , Grin Yu.
Published: September 2014

BiZr, orthorhombic, Cmcm (no. 63), a = 3.858(2) Å, b = 10.770(2) Å, c = 14.325(3) Å, V = 595.2 Å3, Z = 12, Rgt(F) = 0.026, wRref(F) = 0.044, T = 293 K.
Crystal structure of diaqua-bis(pyridine)-μ2-squarato(1,3)-zinc(II), Zn(C4O4)(C5H5N)2(H2O)2
Authors: Kirchmaier R. , Altin E. , Lentz A.
Published: September 2014

C14H14N2O6Zn, orthorhombic, Pbca (no. 61), a = 7.982(1) Å, b = 12.028(2) Å, c = 15.721(2) Å, V = 1509.4 Å3, Z = 4, Rgt(F) = 0.030, wRref(F2) = 0.078, T = 293 K.
Crystal structure of sodium 4-azidobenzenesulfonate, Na[N3C6H4SO3]
Authors: Biesemeier Frank , Harms Klaus , Müller Ulrich
Published: September 2014

C6H4N3NaO3S, monoclinic, P121/c1 (no. 14), a = 17.816(1) Å, b = 8.3131(7) Å, c = 5.9366(5) Å, β = 93.061(6)°, V = 878.0 Å3, Z = 4, Rgt(F) = 0.026, wRref(F2) = 0.073, T = 193 K.
Crystal structure of bis(μ2-aqua)diaquasodium 4-azidobenzenesulfonate monohydrate, Na(H2O)4[N3C6H4SO3] · H2O
Authors: Biesemeier Frank , Harms Klaus , Müller Ulrich
Published: September 2014

C6H14N3NaO8S, monoclinic, P121/c1 (no. 14), a = 7.018(1) Å, b = 27.193(5) Å, c = 7.089(1) Å, β = 92.01(2)°, V = 1352.0 Å3, Z = 4, Rgt(F) = 0.071, wRref(F2) = 0.160, T = 193 K.
Crystal structure of N,N,N′,N′-tetra-m-tolyl-anthracene-9,10-diamine, C42H36N2
Authors: Yu M.-X.
Published: September 2014

C42H36N2, monoclinic, P121/c1 (no. 14), a = 8.279(3) Å, b = 16.998(6) Å, c = 11.812(4) Å, β = 93.599(7)°, V = 1659.0 Å3, Z = 2, Rgt(F) = 0.068, wRref(F2) = 0.161, T = 295 K.
Crystal structure of tetraaqua(4,4′-bipyridine-N,N′)copper(II) fumarate tetrahydrate, Cu(H2O)4(C10H8N2)(C4H2O4) · 4H2O
Authors: Ying E.-B. , Zheng Y.-Q. , Zhou Q.-Q.
Published: September 2014

C14H26CuN2O12, monoclinic, C12/c1 (no. 15), a = 16.631(3) Å, b = 11.155(2) Å, c = 13.096(3) Å, β = 125.08(3)°, V = 1988.3 Å3, Z = 4, Rgt(F) = 0.038, wRref(F2) = 0.094, T = 293 K.
Crystal structure of 5,10,15,20-tetrakis(5′-methylthien-2′-yl)porphyrin, C40H30N4S4
Authors: Bellizzi M. , Foss P. C. D. , Pelto R. , Crundwell G. , Brückner C. , Updegraff J. B. , Zeller M. , Hunter A. D.
Published: September 2014

C40H30N4S4, triclinic, P1̅ (no. 2), a = 6.5126(7) Å, b = 10.499(1) Å, c = 12.635(1) Å, α = 87.818(2)°, β = 79.141(2)°, γ = 86.737(2)°, V = 846.7 Å3, Z = 1, Rgt(F) = 0.057, wRref(F2) = 0.150, T = 100 K.
Crystal structure of aqua[1,3-bis(2-pyridylimino)isoindolinato](salicylato)- copper(II), Cu(C7O3H4)(C18H12N5)(H2O)
Authors: Kaizer J. , Pap J. , Speier G. , Párkányi L.
Published: September 2014

C25H18CuN5O4, triclinic, P1̅ (no. 2), a = 7.300(1) Å, b = 11.985(1) Å, c = 13.190(1) Å, α = 88.15(1)°, β = 78.68(1)°, γ = 78.62(1)°, V = 1109.3 Å3, Z = 2, Rgt(F) = 0.048, wRref(F2) = 0.134, T = 293 K.
Crystal structure of 2-hydroxyimino-3-oxo-3-phenyl-propionic acid ethyl ester, C11H11NO4
Authors: Ramos Silva M. , Matos Beja A. , Paixão J. A. , Lopes S. H. , Cabral Ana M. T. D. P. V. , Rocha Gonsalves A. M. d′A. , Sobral A. J. F. N.
Published: September 2014

C11H11NO4, orthorhombic, Pna21 (no. 33), a = 18.370(4) Å, b = 4.870(1) Å, c = 24.616(2) Å, V = 2202.4 Å3, Z = 8, Rgt(F) = 0.082, wRref(F2) = 0.203, T = 293 K.
Crystal structure of bis(8-chloro-5-(4-methylpiperazinium-1-yl)pyrido- [2,3-b][1,5]benzoxazepine) fumarate – fumaric acid solvate (1:1), (C17H18ClN4O)2(C4H2O4) · C4H4O4
Authors: Dupont L. , Liégeois J.-F.
Published: September 2014

C42H42Cl2N8O10, triclinic, P1̅ (no. 2), a = 9.625(1) Å, b = 9.929(3) Å, c = 11.860(2) Å, α = 108.12(2)°, β = 73.24(1)°, γ = 87.38(1)°, V = 1019.9 Å3, Z = 1, Rgt(F) = 0.043, wRref(F2) = 0.131, T = 293 K.
Crystal structure of diaquatetra(3,5-dinitrobenzoato)tetrasilver(I), Ag4(C7H3N2O6)4(H2O)2
Authors: Xia J. , Wang Z.-G. , Yang L. , Tang L.-L. , Zhu H.-L.
Published: September 2014

C28H16Ag4N8O26, monoclinic, P121/c1 (no. 14), a = 5.667(1) Å, b = 16.915(3) Å, c = 19.694(4) Å, β = 90.38(3)°, V = 1887.8 Å3, Z = 2, Rgt(F) = 0.065, wRref(F2) = 0.177, T = 293 K.
Crystal structure of catena-bis-μ-terephthalato[2,2′-bipyridinecobalt(II)] [aqua-2,2′-bipyridinecobalt(II)], Co2(C8H4O4)2(C10H8N2)2(H2O)
Authors: Chen F. , Hu M.-L. , Ye M.-D. , Xiao H.-P.
Published: September 2014

C36H26Co2N4O9, monoclinic, P121/c1 (no. 14), a = 13.8648(7) Å, b = 17.1789(9) Å, c = 14.1938(7) Å, β = 104.525(1)°, V = 3272.7 Å3, Z = 4, Rgt(F) = 0.076, wRref(F2) = 0.151, T = 298 K.
Crystal structure of 2-(3-methoxyphenylethynyl)-6-methylpyridine, C15H13NO, M-MPEP – a mGluR5 antagonist
Authors: Alagille D. , Baldwin R. M. , Incarvito C. D. , Tamagnan G.
Published: September 2014

C15H13NO, monoclinic, P121/c1 (no. 14), a = 15.986(3) Å, b = 6.760(1) Å, c = 11.415(2) Å, β = 104.63(3)°, V = 1193.5 Å3, Z = 4, Rgt(F) = 0.055, wRref(F2) = 0.139, T = 183 K.
Crystal structure of 4-methylanilinium dihydrogenphosphate, ( p-CH3C6H4NH3)(H2PO4)
Authors: Smirani W. , Ben Slimane A. , Rzaigui M.
Published: September 2014

C7H12NO4P, orthorhombic, Pbca (no. 61), a = 7.790(3) Å, b = 24.645(4) Å, c = 9.867(2) Å, V = 1894.3 Å3, Z = 8, Rgt(F) = 0.048, wRref(F) = 0.053, T = 296 K.
Crystal structure of (3S,4S)-4,5-O-cyclohexylidene-4,5-dihydroxy-3- methylamino-pentanoic acid hydrochloride, (C12H22NO4)Cl
Authors: Frey W. , Henneböhle M. , Jäger V.
Published: September 2014

C12H22ClNO4, monoclinic, P1211 (no. 4), a = 6.2327(3) Å, b = 7.9360(3) Å, c = 14.1536(5) Å, β = 99.709(4)°, V = 690.1 Å3, Z = 2, Rgt(F) = 0.042, wRref(F2) = 0.115, T = 293 K.
Crystal structure of samarium nickel aluminide, Sm4Ni6Al23
Authors: Fornasini M. L. , Raggio R. , Borzone G.
Published: September 2014

Al23Ni6Sm4, monoclinic, C12/m1 (no. 12), a = 15.939(3) Å, b = 4.0967(6) Å, c = 18.320(3) Å, β = 113.09(2)°, V = 1100.4 Å3, Z = 2, Rgt(F) = 0.017, wRobs(F2) = 0.040, T = 293 K.
Crystal structure of dieuropium and distrontium di(lithium, magnesium) trigermanide, M2LixMg2–xGe3 (M= Eu, x = 1.16;M= Sr, x = 0.94)
Authors: Xie Q.-X. , Nesper R.
Published: September 2014

Eu2Ge3Li1.16Mg0.84, orthorhombic, Cmcm (no. 63), a = 4.577(1) Å, b = 19.534(4) Å, c = 7.223(2) Å, V = 645.7 Å3, Z = 4, Rgt(F) = 0.030, wRref(F2) = 0.072, T = 293 K.

Ge3Li0.94Mg1.06Sr2, orthorhombic, Cmcm (no. 63), a = 4.6357(3) Å, b = 19.703(1) Å, c = 7.3239(5) Å, V = 669.0 Å3, Z = 4, Rgt(F) = 0.023, wRref(F2) = 0.047, T = 293 K.
Crystal structure of dithallium(I) octa-μ3-bromohexabromo-octahedrohexamolybdate, Tl2[(Mo6Br8)Br6]
Authors: Xu W. , Zheng Y.-Q. , Wang P.
Published: September 2014

Br14Mo6Tl2, cubic, Pn3̅ (no. 201), a = 13.813(1) Å, V = 2635.4 Å3, Z = 4, Rgt(F) = 0.080, wRref(F2) = 0.147, T = 295 K.
Crystal structure of cobalt aluminum silicide, Co10+xAl23Si9–2x (x = 0.14), the φ phase in the Co-Al-Si system
Authors: Richter K. W. , Prots Yu.
Published: September 2014

Al23Co10.14Si8.72, orthorhombic, Pnma (no. 62), a = 13.852(3) Å, b = 23.055(5) Å, c = 7.340(2) Å, V = 2344.1 Å3, Z = 4, Rgt(F) = 0.035, wRref(F2) = 0.081, T = 293 K.
Crystal structure of 4-ethyl-5-{[(4-methyl-4H-1,2,4-triazol-3-yl)- sulfanyl]methyl}-4H-1,2,4-triazole-3(2H)-thione, C8H12N6S2, the orthorhombic modification
Authors: Mazur L. , Koziol A. E. , Maliszewska-Guz A. , Wujec M. , Pitucha M. , Dobosz M.
Published: September 2014

C8H12N6S2, orthorhombic, Iba2 (no. 45), a = 21.802(4) Å, b = 8.821(2) Å, c = 12.676(4) Å, V = 2437.8 Å3, Z = 8, Rgt(F) = 0.039, wRref(F2) = 0.104, T = 293 K.
Crystal structure of N-methoxy-N-methyl-2-[(4'-nitrophenyl)sulfinyl]- propanamide, C11H14N2O5S
Authors: Zukerman-Schpector J. , Domingues N. L. C. , Mondino M. G. , Reis A. K. C. A. , Rittner R. , Lima F. S.
Published: September 2014

C11H14N2O5S, monoclinic, P121/c1 (no. 14), a = 7.4329(9) Å, b = 23.631(3) Å, c = 7.900(1) Å, β = 110.723(8)°, V = 1297.9 Å3, Z = 4, Rgt(F) = 0.045, wRref(F2) = 0.114, T = 293 K.
Crystal structure of 1-[2,4,6-tris(benzoyloxy)phenyl]ethanone, C29H20O7
Authors: Shi J. , Zhang Z.-T.
Published: September 2014

C29H20O7, monoclinic, P121/c1 (no. 14), a = 9.583(4) Å, b = 25.30(1) Å, c = 19.975(9) Å, β = 96.732(8)°, V = 4809.0 Å3, Z = 8, Rgt(F) = 0.071, wRref(F2) = 0.189,T = 298 K.
Crystal structure of dimethylammonium bis(salicylato)borate, [NH2(CH3)2][BO4(C7H4O)2]
Authors: Li P. , Liu Z.-H.
Published: September 2014

C16H16BNO6, orthorhombic, Aba2 (no. 41), a = 8.544(7) Å, b = 19.68(2) Å, c = 9.117(7) Å, V = 1532.9 Å3, Z = 4, Rgt(F) = 0.052, wRref(F2) = 0.136, T = 298 K.
Crystal structure of dimethanol-bis(1,3-bis(3,5-dimethylpyrazol-1-yl)- propan-2-olato)dicopper(II) dibromide, [Cu2(C13H19N4O)2(CH3OH)2]Br2
Authors: Zhang G.-F. , Dou Y.-L. , She J.-B. , Yin M.-H.
Published: September 2014

C28H46Br2Cu2N8O4, orthorhombic, Pbca (no. 61), a = 11.914(4) Å, b = 16.368(5) Å, c = 18.237(6) Å, V = 3556.4 Å3, Z = 4, Rgt(F) = 0.060, wRref(F2) = 0.185, T = 298 K.
Crystal structure of 3,5-dinitro-2-pyridone, C5H3NO(NO2)2
Authors: Zhang G.-F. , She J.-B. , Dou Y.-L. , Fan R.
Published: September 2014

C5H3N3O5, orthorhombic, Pna21 (no. 33), a = 12.335(4) Å, b = 9.636(3) Å, c = 5.738(2) Å, V = 682.0 Å3, Z = 4, Rgt(F) = 0.031, wRref(F2) = 0.085, T = 298 K.
Crystal structure of catena-aquatris(1H-imidazole-N)(μ-sulfato)copper(II), Cu(H2O)(C3H4N2)3(SO4)
Authors: Fu F. , Guo J.-X. , Li D.-S. , Tang L. , Zhang M.-L. , Wang J.-W.
Published: September 2014

C9H14CuN6O5S, monoclinic, P121/n1 (no. 14), a = 11.723(2) Å, b = 8.651(2) Å, c = 13.839(3) Å, β = 91.703(4)°, V = 1402.8 Å3, Z = 4, Rgt(F) = 0.046, wRref(F2) = 0.133, T = 296 K.
Crystal structure of (3R,6S,4'S)-2-benzyl-3-(2',2'-dimethyl[1',3']dioxolan- 4'-yl)-4-methoxy-6-phenyl-3,6-dihydro-2H-1,2-oxazine, C23H27NO4
Authors: Chowdhury M. A. , Brüdgam I. , Hartl H. , Reißig H.-U.
Published: September 2014

C23H27NO4, monoclinic, P1211 (no. 4), a = 10.053(3) Å, b = 9.859(3) Å, c = 10.202(3) Å, β = 96.087(6)°, V = 1005.4Å3, Z = 2, Rgt(F) = 0.054, wRref(F2) = 0.138, T = 173 K.
Crystal structure of 1,2,5-trimethyl-1,2,3,4-tetrahydropyrido[ 4,3-b]carbazole (guatambuine), C18H20N2, from Aspidosperma subincanum Mart.
Authors: De Simone C. A. , Malta V. R. S. , Lamenha G. S. , Humberto M. M. S. , Porto K. R. A. , Sant' Ana A. E. G
Published: September 2014

C18H20N2, orthorhombic, P212121 (no. 19), a = 11.587(5) Å, b = 8.130(5) Å, c = 15.239(5) Å, V = 1435.5 Å3, Z = 4, Rgt(F) = 0.055, wRref(F2) = 0.137, T = 293 K.
Crystal structure of bismuth triiodate dihydrate, Bi[IO3]3 · 2H2O
Authors: Phanon D. , Gautier-Luneau I.
Published: September 2014

BiH4I3O11, triclinic, P1̅ (no. 2), a = 7.056(2) Å, b = 7.337(1) Å, c = 10.740(1) Å, α = 95.06(1)°, β = 106.16(1)°, γ = 109.56(1)°, V = 493.0 Å3, Z = 2, Rgt(F) = 0.035, wRref(F2) = 0.090, T = 293 K.
Crystal structure of indium triiodate trihydrate, In[IO3]3 · 3H2O
Authors: Phanon D. , Gautier-Luneau I.
Published: September 2014

H6I3InO12, triclinic, P1̅ (no. 2), a = 6.862(1) Å, b = 7.282(2) Å, c = 11.137(3) Å, α = 94.01(2)°, β = 107.75(1)°, γ = 93.59(1)°, V = 526.7 Å3, Z = 2, Rgt(F) = 0.034, wRref(F2) = 0.089, T = 293 K.
Crystal structure of potassium scandium (monophosphate-hydrogenmonoborate- monophosphate), KSc[BP2O8(OH)]
Authors: Menezes P. W. , Hoffmann S. , Prots Yu. , Kniep R.
Published: September 2014

BHKO9P2Sc, triclinic, P1̅ (no. 2), a = 5.2696(2) Å, b = 8.2739(8) Å, c = 8.3890(5) Å, α = 88.22(1)°, β = 79.701(6)°, γ = 86.67(1)°, V = 359.2 Å3, Z = 2, Rgt(F) = 0.032, wRref(F2) = 0.075, T = 295 K.
Crystal structure of praseodymium dimolybdenum disilicide carbide, PrMo2Si2C
Authors: Dashjav E. , Schnelle W. , Wagner F. R. , Kreiner G. , Kniep R.
Published: September 2014

CMo2PrSi2, tetragonal, P4/mmm (no. 123), a = 4.2139(3) Å, c = 5.4093(4) Å, V = 96.1 Å3, Z = 1, Rgt(F) = 0.020, wRref(F2) = 0.042, T = 295 K.
Crystal structure of carbohydrazidium(1+) p-toluenesulfonate, (NH2NHCONHNH3)[CH3C6H4SO3]
Authors: Yang L. , Yu W. , Wu T. , Zhang T.-L. , Zhang J.-G. , Guo J.-Y. , Wu R.-F. , Ren F.-J.
Published: September 2014

C16H28N8O8S2, orthorhombic, Pbca (no. 61), a = 10.646(1) Å, b = 8.185(1) Å, c = 26.402(4) Å, V = 2300.6 Å3, Z = 4, Rgt(F) = 0.038, wRref(F2) = 0.093, T = 293 K.
Refinement of the crystal structure of (E)-1,3-diphenyl-2-propen-1-one, C15H12O
Authors: Wu M.-H. , Yang X.-H. , Zou W.-D. , Liu W.-J. , Li C.
Published: September 2014

C15H12O, orthorhombic, Pbcn (no. 60), a = 10.932(1) Å, b = 11.860(1) Å, c = 17.996(2) Å, V = 2333.3 Å3, Z = 8, Rgt(F) = 0.060, wRref(F2) = 0.173, T = 292 K.
Crystal structure of 2′-hydroxyacetophenone nicotinoylhydrazone monohydrate, C14H15N3O3 · H2O
Authors: Tai X.-S. , Kong F.-Y.
Published: September 2014

C14H15N3O3, triclinic, P1̅ (no. 2), a = 8.680(2) Å, b = 8.877(2) Å, c = 9.273(2) Å, α = 81.28(3)°, β = 86.26(3)°, γ = 70.48(3)°, V = 665.5 Å3, Z = 2, Rgt(F) = 0.064, wRref(F2) = 0.177, T = 291 K.
Crystal structure of bis(1,10-phenanthroline-N,N′)bis(2-chlorobenzoato)- lead(II) hydrate (1:2.5), [Pb(C7H4O2Cl)2(C12H8N2)2] · 2.5H2O
Authors: Guo H.-M. , Zhang B.-S. , Wang Y.-H.
Published: September 2014

C38H29Cl2N4O6.5Pb, triclinic, P1̅ (no. 2), a = 11.548(2) Å, b = 12.532(3) Å, c = 13.661(3) Å, α = 95.34(3)°, β = 112.60(3)°, γ = 103.23(3)°, V = 1740.4 Å3, Z = 2, Rgt(F) = 0.037, wRref(F2) = 0.082, T = 293 K.
Crystal structure of bis[(1,3-bis(4-pyridinium)propane)]- [β-hexacosaoxooctamolybdate(VI)], (C13H16N2)2[Mo8O26]
Authors: Wang C.-C.
Published: September 2014

C26H32Mo8N4O26, monoclinic, P121/c1 (no. 14), a = 10.589(2) Å, b = 10.007(2) Å, c = 19.662(4) Å, β = 100.85(3)°, V = 2046.2 Å3, Z = 2, Rgt(F) = 0.023, wRref(F2) = 0.056, T = 293 K.
Crystal structure of acetato-μ-N,N′-bis(salicylidene)-3-methyl- 3-aza-1,5-pentanediaminocobalt(III), Co(C2H3O2)(C21H25N3O2)
Authors: Xu S.-P. , Liu C.-H. , Wang S.-F.
Published: September 2014

C23H28CoN3O4, monoclinic, P121/n1 (no. 14), a = 9.400(4) Å, b = 19.203(5) Å, c = 12.112(5) Å, β = 92.33°, V = 2184.5 Å3, Z = 4, Rgt(F) = 0.066, wRref(F2) = 0.202, T = 293 K.
Crystal structure of tetrakis[(4-methyl-pyridin-2-yl)-trimethylsilanylamido] zirconium(IV), Zr(C9H15N2Si)4
Authors: Noor A. , Irrgang T. , Kempe R.
Published: September 2014

C36H60N8Si4Zr, triclinic, P1̅ (no. 2), a = 12.0360(6) Å, b = 18.8040(9) Å, c = 21.581(1) Å, α = 69.448(4)°, β = 75.278(4)°, γ = 88.159(4)°, V = 4414.5 Å3, Z = 4, Rgt(F) = 0.035, wRref(F2) = 0.101, T = 191 K.
Crystal structures of the methylene chloride disolvates of tetrakis(3,5- dimethoxyphenyl)porphyrin and its isotypic copper(II) and nickel(II) complexes, C52H46N4O8 · 2CH2Cl2, Cu(C52H44N4O8) · 2CH2Cl2, Ni(C52H44N4O8) · 2CH2Cl2
Authors: Zeller M. , DiMuzio S. J. , Bee K. , Clemente J. , Frederick J. , Fucci A. , Gordon L. , Harper A. , Kasmar A. , Kasmar C. , Polomsky S. , Simmons A. , Smallsreed D. , Underwood T. , Hunter A. D.
Published: September 2014

C54H50Cl4N4O8, triclinic, P1̅ (no. 2), a = 11.295(1) Å, b = 11.255(1) Å, c = 11.797(1) Å, α = 108.904(2)°, β = 101.091(2)°, γ = 110.992(2)°, V = 1241.4 Å3, Z = 1, Rgt(F) = 0.056, wRref(F2) = 0.135, T = 100 K.

C54H48Cl4CuN4O8, triclinic, P1̅ (no. 2), a = 11.2204(5) Å, b = 11.3499(6) Å, c = 11.7610(6) Å, α = 109.187(1)°, β = 100.830(1)°, γ = 110.681(1)°, V = 1242.7 Å3, Z = 1, Rgt(F) = 0.033, wRref(F2) = 0.092, T = 100 K.

C54H48Cl4N4NiO8, triclinic, P1̅ (no. 2), a = 11.196(1) Å, b = 11.329(1) Å, c = 11.785(1) Å, α = 109.486(2)°, β = 101.230(2)°, γ = 110.607(2)°, V = 1233.8 Å3, Z = 1, Rgt(F) = 0.040, wRref(F2) = 0.110, T = 100 K.
Crystal structure of bis(2,2′-biimidazol-1-ium) tetrachloroferrate(III) chloride, (C6H7N4)2[FeCl4]Cl
Authors: Hu M.-L. , Chen F.
Published: September 2014

C12H14Cl5FeN8, monoclinic, P121/c1 (no. 14), a = 7.1902(5) Å, b = 12.7155(9) Å, c = 21.753(2) Å, β = 96.405(1)°, V = 1976.4 Å3, Z = 4, Rgt(F) = 0.085, wRref(F2) = 0.166, T = 298 K.
Crystal structure of theophylline-7-acetic acid, C9H10N4O4
Authors: Zhang L.-J. , Liu M.-C. , Ding J.-C. , Wu H.-Y.
Published: September 2014

C9H10N4O4, monoclinic, P121/n1 (no. 14), a = 9.542(1) Å, b = 7.2415(9) Å, c = 14.446(2) Å, β = 98.657(2)°, V = 986.8 Å3, Z = 4, Rgt(F) = 0.053, wRref(F2) = 0.138, T = 298 K.
Crystal structure of N, N′-bis(salicylidene)-1,10-decanediamine, C10H20(NCHC6H4OH)2
Authors: Yu Y.-Y.
Published: September 2014

C24H32N2O2, monoclinic, C12/c1 (no. 15), a = 46.409(9) Å, b = 4.800(1) Å, c = 9.987(2) Å, β = 98.10(3)°, V = 2202.4 Å3, Z = 4, Rgt(F) = 0.047, wRref(F2) = 0.142, T = 296 K.
Crystal structure of N-(diphenyl)methyl-N-(3′,3′-dimethyl-2′-oxo)butyl- 2(R),3(R)-epoxybutyramide, C23H27NO3
Authors: Tinant B. , Laurent M. , Marchand-Brynaert J.
Published: September 2014

C23H27NO3, monoclinic, P1211 (no. 4), a = 8.669(3) Å, b = 22.880(5)Å, c = 10.220(3)Å, β = 96.04(2)°, V = 2015.9Å3, Z = 4, Rgt(F) = 0.039, wRref(F2) = 0.106, T = 125 K.
Crystal structures of catena-(tris(μ-betaine-O,O′)manganese(II)) tetrachlorozincate and catena-(tris(μ-betaine-O,O′)manganese(II)) tetrachlorocobaltate, [{(CH3)3NCH2COO}3Mn][MCl4] (M= Zn, Co)
Authors: Wiehl L. , Schreuer J. , Haussühl E.
Published: September 2014

C15H33Cl4MnN3O6Zn, trigonal, P3̅ (no. 147), a = 12.7751(5) Å, c = 9.0835(2) Å, V = 1283.9 Å3, Z = 2, Rgt(F) = 0.032, wRref(F2) = 0.083, T = 293 K.

C15H33Cl4CoMnN3O6, trigonal, P3̅ (no. 147), a = 12.7832(7) Å, c = 9.0769(4) Å, V = 1284.6 Å3, Z = 2, Rgt(F) = 0.028, wRref(F2) = 0.076, T = 293 K.
Crystal structure of dimethyl (2S,3R,3aS,4S,5R,6R)-6-iodomethyl-4,5- isopropylidenedioxy-hexahydropyrrolo[1,2-b]pyrazole-2,3-dicarboxylate, C14H21IN2O6
Authors: Frey W. , Shaw D. , Jégou A. , Jäger V.
Published: September 2014

C14H21IN2O6, orthorhombic, P212121 (no. 19), a = 9.748(1) Å, b = 11.701(2) Å, c = 15.552(2) Å, V = 1773.9 Å3, Z = 4, Rgt(F) = 0.050, wRref(F2) = 0.120, T = 293 K.
Crystal structure of bis(1,10-phenanthroline-N,N′)bis(2,4-dimethylbenzoato- O,O′)tetrakis(μ-2,4-dimethylbenzoato-O,O′)disamarium(III), Sm2(C9H9O2)6(C12H8N2)2
Authors: Zhang T.-T. , Li X. , Ju Y.-L.
Published: September 2014

C78H70N4O12Sm2, monoclinic, C12/c1 (no. 15), a = 27.523(3) Å, b = 15.699(2) Å, c = 16.048(2) Å, β = 101.123(2)°, V = 6803.7 Å3, Z = 4, Rgt(F) = 0.026, wRref(F2) = 0.063, T = 294 K.
Painful fat necrosis resulting from insulin injections
Authors: Hanson P , Pandit M , Menon V , Roberts S , Barber T M
Published: September 2014

The case is a 34-year-old woman with long-standing type 1 diabetes mellitus with existing follow-up in the outpatient clinic at the Warwickshire Institute for the Study of Diabetes, Endocrinology and Metabolism, UHCW. She had maintained good glycaemic control and glycaemic stability with basal bolus regimen for many years. She had not developed any diabetes-related complications and had no other co-morbidities. Six months ago, she presented to A&E with sudden-onset, well-localised and severe pain in the right iliac fossa, just lateral to the para-umbilical area. Her biochemistry was normal. Ultrasound scan, however, revealed a right-sided ovarian cyst, which was thought to have caused pain to her. She was discharged from A&E with simple analgesia. On subsequent gynaecological follow-up 4 weeks later, her pain remained severe and examination revealed an exquisitely tender subcutaneous nodule at the same location measuring 2 cm in diameter. Magnetic resonance imaging (MRI) scan at the time revealed a 1 cm mass in the subcutaneous adipose tissue, which co-localised to her pain. The mass demonstrated a central fat signal surrounded by a peripheral ring: observations consistent with fat necrosis. There were other smaller subcutaneous nodules also observed in the left para-umbilical area. Subsequent surgical resection of the main area of fat necrosis was performed. The patient made an excellent recovery and her pain resolved post-operatively. Histology confirmed the presence of fat necrosis. Fat necrosis is a rare complication of s.c. insulin injection. This case illustrates the importance of considering this diagnosis in patients who inject insulin and develop localised injection-site pain.

Learning points

Fat necrosis is a rare complication of insulin injections that can manifest with severe, persistent and well-localised pain.

Fat necrosis can masquerade as other pathologies causing diagnostic confusion.

The imaging modality of choice for accurate diagnosis of fat necrosis is MRI.

Histological confirmation of fat necrosis is important.

Appropriate management of localised fat necrosis is surgical excision, with avoidance of further insulin injections into the affected area.
Energy Efficient Key Management Scheme for Wireless Sensor Networks
Authors: Suganthi N. , Vembu Sumathy
Published: September 2014

A Wireless Sensor Network (WSN) is composed of a large number of sensor nodes deployed over a geographical area. Each node is a low-power device that integrates computing, wireless communication, and sensing abilities. Many applications that make use of sensor networks require secure communication. Designing an efficient key establishment scheme is of great importance to the data security in Wireless Sensor Networks. The traditional cryptographic techniques are impractical in Wireless Sensor Networks because of associated high energy and computational overheads.This algorithm supports the establishment of three types of keys for each sensor node, an individual key shared with the base station, a pair wise key shared with neighbor sensor node, and a group key that is shared by all the nodes in the network. The algorithm used for establishing and updating these keys are energy efficient and minimizes the involvement of the base station. Polynomial function is used in the study to calculate the keys during initialization, membership change and key compromise. Periodically the key will be updated. To overcome the problem of energy insufficiency and memory storage and to provide adequate security, the energy efficient scheme is proposed. It works well in undefined deployment environment. Unauthorized nodes should not be allowed to establish communication with network nodes. This scheme when compared with other existing schemes has a very low overhead in computation, communication and storage.
Efficiency of a Combined Protection Method against Correlation
Authors: Teodorescu Horia-Nicolai L. , Iftene Emanuel-Florin
Published: September 2014

We analyze the eciency of the masking of instruction patterns using a chaotic driven clock and power supply, in front of a side attack intruding the power supply of a microsystem. The differential analysis is supposedly conducted by correlation power analysis. We demonstrate that the use of a chaotically-driven masking based on relatively simple circuits may be a signicant candidate for the protection of embedded systems.
Spectrum Migration Approach Based on Pre-decision Aid and Interval Mamdani Fuzzy Inference in Cognitive Radio Networks
Authors: Wang Zhendong , Wang Huiqiang , Lv Hongwu , Feng Guangsheng
Published: September 2014

This study intends to improve the QoS of SUs and CRNs performance. A novel spectrum migration approach based on pre-decision aid and interval Mamdani fuzzy inference is presented. we first define spectrum migration factors as spectrum characteristic metrics for spectrum migration decision. In addition, we use predecision aid to reduce system complexity and improve spectrum migration efficiency. To shorten spectrum migration decision time and seek the optimal spectrum holes, interval Mamdani fuzzy inference is put forward. Finally, simulation results show the proposed approach can inhibit the upward trend of service retransmission probability and average migration times effectively, and improve the effective utilization of CRNs spectrum resource significantly.
Implications of HAM/TSP functional incapacity in the quality of life
Authors: Shublaq Marcia , Orsini Marco , Puccioni-Sohler Marzia
Published: September 2014

OBJECTIVE: To identify the functional status and quality of life of HAM/TSP patients. METHOD: We evaluated prospectively 30 HAM/TSP patients (20 females) seen in the Neuroinfection Clinic of the HUGG. The functional capacity was analyzed by the functional independence measure (FIM), the expanded disability status (EDSS) scale and the Osame's motor disability score (OMDS). The quality of life was assed by the Short-Form Health Survey 36 (SF-36)TM. RESULTS: All patients need assistance device. The FIM, OMDS and EDSS scores classified 70%, 67% and 67% of the patients as dependent, respectively. The lowest scores of the SF-36 survey were found in the domains related to the physical health (D1, D2), role-emotional functioning (D7) and social functioning (D6). CONCLUSION: Our data suggest that the HAM/TSP physical impairment has an impact in the emotional and social issues, considering the limitation in the daily activities.
Prescription patterns of enzyme-containing products in South Africa over a 2-year period
Authors: Truter Ilse
Published: September 2014

Enzymes are traded in five categories, namely medical (intervention), diagnostic (detection and quantification), molecular biology, biofuel and industrial. Therapeutic enzymes have been investigated for different uses, for example, for the treatment of genetic disorders, blood clotting disorders, cancer and infectious diseases and for burn debridement. No studies on the prescription of enzyme-containing products in South Africa could be found. Enzymes are classified in the Monthly Index of Medical Specialities under digestants, enzymes and fibrinolytics. The primary aim of this study was to investigate the prescription patterns and cost of enzyme-containing products in South Africa. A private health-care medicines claims database for 2010 and 2011 of approximately 4.5 million records was analysed retrospectively. Enzyme-containing products constituted a small percentage of medical insurance claims (only 0.02% of approximately 4.5 million claims for products and procedures), yet they were relatively expensive. A total of 906 products was prescribed at a cost of almost ZAR2 million over the 2 years. Hyaluronidase was the most frequently prescribed (60.04%), followed by pancreatin-containing products (34.66%). Pancreatin (lipase/ protease/amylase) is primarily used in the management of pancreatic exocrine insufficiency. The average cost per hyaluronidase prescription paid by the medical insurance schemes was ZAR280. Other enzyme-containing products prescribed were imiglucerase, alteplase and tenecteplase. Imiglucerase was overall the most expensive. Alteplase, tenecteplase and streptokinase are antithrombotic enzymes that are used in the treatment of acute myocardial infarction or ischaemic stroke. Streptokinase, regarded as the most affordable antithrombotic enzyme, was not prescribed during the period under study. With the growing opportunities for enzymes for therapeutics, the use of enzyme-containing products which are comparatively expensive require cost-effectiveness studies.